CD8A and cervical cancer: Moreover, there was a significant rise in the population of activated CD8+ T cells and humoral responses among those receiving the vaccine rather than placebo-received ones, suggesting VGX-3100 as a promising DNA vaccine to thoroughly elicit adaptive immunity against HPV-driven cervical cancer [19].